Huntingtons Disease Treatment Market Size, Sector / Industry Report & Analysis, 2023 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Huntingtons Disease Treatment Market


The global Huntingtons Disease Treatment market size is projected to reach US$ 2776.83 million by 2026, from US$ 398.57 million in 2020, at a CAGR of 38.2% during 2021-2026. Increased uptake of improved symptomatic therapies, promising disease-modifying therapies in the developmental pipeline, rise in target population, and favorable government initiatives are some of the key factors contributing to market growth.

Huntingtons disease (HD) is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. HD accounts for approximately 30,000 cases annually in U.S. and Juvenile HD accounts for nearly 16% of all cases. Both men and women are affected equally, and the prevalence is uniform between all races and ethnic groups.

Currently, only two symptom-alleviating therapies are specifically approved for HD: Xenazine and Austedo. The market is witnessing a shift in terms of a drug-development approach from conventional symptomatic therapies to disease-modifying therapies, driven by a better understanding of the pathogenesis of this disorder. Rapid uptake of improved symptomatic therapies and pipeline breakthroughs will remain the major factor driving the market over the next few years.

Market Segmentation, Outlook & Viewpoint: Global Huntingtons Disease Treatment Market

Treatment Market Segmentation & Outlook (Revenue, USD Million, 2017 - 2023)

  
Symptomatic Therapy
  
Disease-Modifying Therapy

Key Players, Recent Developments & Regional Insights: Global Huntingtons Disease Treatment Market

Huntingtons disease can be caused by dopamine imbalance, which contributes both to involuntary movements such as chorea as well as decelerating voluntary movements. Due to lack of approved medications, the current clinical needs of HD are largely served by off-label use of conventional antipsychotics and anti-epileptics prescribed for treatment of severe emotional as well as motor impairment characteristics.

The Huntingtons disease treatment market is expected to witness novel product launches, including approval of several disease-modifying therapies. Current research in HD focuses on using novel treatments such as immuno-modulating therapies, gene therapy (using antisense oligonucleotides, micro RNAs (miRNA), mRNA splicing, and zinc-finger DNA binding protein (ZFP)).

Nucleotide-based gene silencing therapies such as RNAi and antisense oligonucleotides offer promising treatment options. IONIS-HTTRx is the first drug to demonstrate significant, dose-dependent reductions of mutant Huntingtin (mHTT) protein in HD patients. Wave Life Sciences allele-specific drugs have the potential to target more than half of the HD patient population. Both drugs are expected to contribute significantly to market growth.

Pipeline Insights

High unmet needs within the market present a key commercial opportunity to develop breakthrough disease-modifying therapies. The Huntingtons disease pipeline is expected to witness new developments over the next decade as several privately-held and innovation-driven pharmaceutical companies venture into the HD treatment arena. The introduction of disease-modifying drugs is poised to transform the market landscape. With ongoing research aiding in further understanding its pathogenesis, there are increasingly significant opportunities for drug companies to develop new drugs with novel mechanisms of action.

Lowering levels of mHTT has been demonstrated to be therapeutically beneficial for HD. At present, more than 20 products are being studied for treatment for Huntingtons disease in various stages of clinical investigation. Waves PRECISION-HD program is the first to follow an allele-specific approach, which is aimed at targeting the underlying cause of Huntingtons disease.
Stem cell therapy is also generating interest as a potential treatment for the condition. Currently, Cellavita, in collaboration with Azidus Pharma, is investigating cell therapy CELLAVITA-HD in Phase I ADORE-DH trial.

Country Insights

U.S. dominated the market with more than 60.0% share in 2016 and is projected to maintain the leading position through 2023. Multiple product launches during the forecast period, increased adoption of novel therapeutics, and presence of key manufacturers in the country are a few factors responsible for its dominance.

Huntingtons disease is notably rare in Japan, with a prevalence of less than 1,000 cases annually. It is expected that Japan will register the slowest market expansion through the forecast period, among other major markets.
Huntingtons Disease Treatment Market Share Insights

Key players in the industry include Valeant Pharmaceuticals, Teva Pharmaceuticals, Wave Life Sciences, Ionis Pharmaceuticals/ Roche, Raptor Pharmaceuticals, and Prana Biotechnology. Several companies are making licensing deals and strategic collaborations to improve clinical success and develop novel treatment for the condition. There were nine licensing and acquisition deals involving drugs for Huntingtons during 2013-2018.

Valeant led the market until 2017, supported by Xenazines strong competitive position as the only product approved for treatment of chorea associated with HD. However, Valeant is expected to face significant competition due to generic penetration and launch of Teva Pharmaceuticals Austedo. Austedos key patents expire in 2031, which gives Teva significant commercial lead for further market penetration.

UniQures AMT-130 was the first investigational AAV-gene therapy to receive orphan drug designation by the U.S. FDA in October 2017 and by the EMA in January 2018. Vaccinexs VX-15 represents the first-time use of monoclonal antibody for treatment of HD. In February 2016, VX 15 received Fast Track Designation for the treatment of HD. Vaccinex initiated Phase II SIGNAL trial in June 2015 and top-line data is expected by the fourth quarter of 2018.  Several other biopharmaceutical companies are focused on development of novel treatments in areas of unmet therapeutic needs of Huntingtons disease.

Key Insights Covered: Global Huntingtons Disease Treatment Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Huntingtons Disease Treatment industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Huntingtons Disease Treatment industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Huntingtons Disease Treatment industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Huntingtons Disease Treatment industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Huntingtons Disease Treatment industry.

Research Methodology: Global Huntingtons Disease Treatment Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other